MedX Health Corp. Provides Update on the Release of Its First Quarter 2020 Interim Financial Statements and Related Disclosures, and Retirement of a Director

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) provides an update on the filing of its Interim Financial Statements and related Disclosures for the First Quarter of fiscal 2020 (the “Interim Disclosures”) which was delayed owing to COVID-19 related issues. As previously announced in its Press Release dated May 27, 2020, the Company anticipates that the Interim Disclosures will be filed by July 13, 2020.

In relation to the delay in filing of the Interim Disclosures, MedX relies on the provisions of Ontario Instrument 51-502, Temporary Exemption from Certain Corporate Finance Requirements and corresponding Instruments in the other jurisdictions in which the Company is a reporting issuer.

The Company also announces that, as anticipated in its Press Release dated June 18, 2020, Scott Spearn has retired from the Board of Directors effective June 30, 2020.

MedX confirms that there have been no material business developments other than as disclosed in its Press Releases and previous filings, and further confirms that Management and other insiders of the Company have been, since April 28, 2020, and continue to be subject to a trading black-out policy that reflects the principles in section 9 of National Policy 11-207, Failure to-File Cease Trade Orders and Revocations in Multiple Jurisdictions, which will remain in effect until the Interim Disclosures have been filed.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200630006083/en/

Rob von der Porten
MedX Health Corp
[email protected]